Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID

Infection and Chemotherapy, Journal Year: 2024, Volume and Issue: 56(1), P. 122 - 122

Published: Jan. 1, 2024

"Long COVID" is a term used to describe condition when the symptoms and signs associated with coronavirus disease 2019 (COVID-19) persist for more than three months among patients infected COVID-19; this has been reported globally poses serious public health issue. Long COVID can manifest in various forms, highlighting need appropriate evaluation management by experts from fields. However, due lack of clear clinical definitions, knowledge pathophysiology, diagnostic methods, treatment protocols, it necessary develop best standard guidelines based on scientific evidence date. We developed guideline diagnosing treating long analyzing latest research data collected start COVID-19 pandemic until June 2023, along consensus expert opinions. This provides recommendations diagnosis that be applied practice, total 32 key questions related COVID. The should comprehensive, including medical history, physical examination, blood tests, imaging studies, functional tests. To reduce risk developing COVID, vaccination antiviral during acute phase are recommended. will revised there reasonable updates availability new

Language: Английский

---

Prevalence and Determinants of Long-term Post-COVID Conditions in the United States: 2022 Behavioral Risk Factor Surveillance System

The American Journal of Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 1, 2024

Language: Английский

---

Work ability and return-to-work of patients with post-COVID-19: a systematic review and meta-analysis

BMC Public Health, Journal Year: 2024, Volume and Issue: 24(1)

Published: July 7, 2024

Abstract Background In addition to several sequelae of post-COVID-19, individuals also experience significant limitations in work ability, resulting negative consequences for the return-to-work (RTW) process. This systematic review and meta-analysis were conducted assess impact post-COVID-19 on ability RTW previously infected with SARS-CoV-2. Methods Studies patients (more than 12 weeks after an acute SARS-CoV-2 infection) regarded eligible inclusion. Systematic search literature was performed up March 2023 using five databases (MEDLINE, EMBASE, CINAHL, CENTRAL WHO COVID 19). Study selection followed Preferred Reporting Items Review Meta-analysis (PRISMA) Statement. A estimated overall success rate RTW. The risk bias included studies evaluated Newcastle Ottawa Scale (NOS). Results 19 relevant studies, published between 2021 2023, review, involving 21.155 from 14 different countries. findings indicate that a proportion persistent symptoms functional impairments, fatigue being most prominent symptom. These can have considerable (negative) individuals’ physical psychological capacity participate work-related activities, leading lower increased absenteeism. is complex, approximately 60.9% successfully returning or more following infection. Among those who work, number need modifications their duties hours cope residual impairments. Factors such as workplace accommodations, supportive policies, occupational rehabilitation programs play crucial role facilitating successful Conclusions underscores substantial outcomes. implications this research highlight healthcare providers, employers, policymakers collaborate creating inclusive environments implementing tailored support recovering post-COVID-19. Further should focus long-term follow-up mixed methods gain comprehensive understanding PROSPERO registration CRD42023385436.

Language: Английский

---

Diabetes Mellitus, Energy Metabolism, and COVID-19

Endocrine Reviews, Journal Year: 2023, Volume and Issue: 45(2), P. 281 - 308

Published: Nov. 2, 2023

Abstract Obesity, diabetes mellitus (mostly type 2), and COVID-19 show mutual interactions because they are not only risk factors for both acute chronic manifestations, but also alters energy metabolism. Such metabolic alterations can lead to dysglycemia long-lasting effects. Thus, the pandemic has potential a further rise of pandemic. This review outlines how preexisting spanning from excess visceral adipose tissue hyperglycemia overt may exacerbate severity. We summarize different effects SARS-CoV-2 infection on key organs tissues orchestrating metabolism, including tissue, liver, skeletal muscle, pancreas. Last, we provide an integrative view derangements that occur during COVID-19. Altogether, this allows better understanding occurring when fire starts small flame, thereby help reducing impact

Language: Английский

---

Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial

Journal of Infection, Journal Year: 2023, Volume and Issue: 87(5), P. 392 - 402

Published: Sept. 9, 2023

•Phase 3 trial evaluating molnupiravir for post-exposure prophylaxis of COVID-19. •About 84% the population had anti-SARS-CoV2 antibodies at baseline. •Day 14 COVID-19 rates (molnupiravir 6.5%, placebo 8.5%) were similar between arms. •Onset was mostly after end therapy in arm. •Molnupiravir well-tolerated but did not meet superiority criterion. Objectives To evaluate efficacy and safety intra-household (PEP) Methods MOVe-AHEAD a randomized, controlled, double-blind, phase comparing (800 mg twice daily 5 days) with placebo. Eligible participants adult, unvaccinated, asymptomatic household contacts patients laboratory-confirmed The primary endpoint incidence through day modified intention-to-treat (MITT) (those who received ≥1 dose study intervention) without detectable SARS-CoV-2 baseline, termed MITT-VN population. Superiority prespecified as stratified one-sided p-value <0.0249 treatment difference this endpoint. Results MITT comprised 763 randomized to 764 placebo; 83.6% anti-SARS-CoV-2 In population, 6.5% 8.5% (one-sided p-value: 0.0848). arm, 25/35 events (71%) occurred completion (versus 17/49 [35%] placebo). Adverse event low Conclusions Molnupiravir criterion, possibly influenced part by high pre-existing immunity

Language: Английский

---

Amino acids, post-translational modifications, nitric oxide, and oxidative stress in serum and urine of long COVID and ex COVID human subjects

Amino Acids, Journal Year: 2023, Volume and Issue: 55(9), P. 1173 - 1188

Published: July 29, 2023

Abstract In this study, we investigated the status of amino acids, their post-translational modifications (PTM), major nitric oxide (NO) metabolites and malondialdehyde (MDA) as a biomarker oxidative stress in serum urine samples long COVID (LoCo, n = 124) ex (ExCo, 24) human subjects collected 2022. Amino acids were measured by gas chromatography–mass spectrometry (GC–MS) methods using stable-isotope labelled analogs internal standards. There no differences with respect to circulating excretory arginine asymmetric dimethylarginine (ADMA). LoCo participants excreted higher amounts guanidino acetate than ExCo (17.8 ± 10.4 µM/mM vs. 12.6 8.86 µM/mM, P 0.005). By contrast, lower advanced glycation end-product (AGE) N G -carboxyethylarginine (CEA) did (0.675 0.781 1.16 2.04 0.0326). The concentrations MDA not differ between groups, indicating elevated or ExCo. concentration nitrite was compared (1.96 0.92 µM 2.56 1.08 µM; AUC, 0.718), suggesting altered NO synthesis endothelium. correlated inversely symptom anxiety ( r − 0.293, 0.0003). creatinine-corrected urinary excretion Lys its metabolite L-5-hydroxy-Lys positively toes 0.306, 0.00027) sore throat 0.302, Our results suggest that acid metabolism, PTM are severely affected COVID. may have reservoir

Language: Английский

---

Prevalence and factors associated with depression and anxiety among COVID-19 survivors in Dhaka city

Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 15

Published: Jan. 23, 2024

Background Coronavirus disease 2019 (COVID-19) is a global public health concern. Evidence shows that depression and anxiety are common among patients with COVID-19 after recovery. About one-third of the total cases in Bangladesh have been reported Dhaka city. Therefore, study aimed to evaluate prevalence survivors city as well identify factors associated these mental conditions. Methods A cross-sectional was carried out 384 aged 18 years or older. Data collection done through face-to-face telephone interviews using semi-structured questionnaire. Patient Health Questionnaire (PHQ-9) Generalized Anxiety Disorder (GAD-7) scales were used assess anxiety, respectively. Binary logistic regression analysis performed predictors recovered from COVID-19. Results The overall 26.0% 23.2%, respectively survivors. respondents who ≥60 2.62 3.02 times more likely report depressive symptoms, than those 39 years. Hospitalised had 2.18 higher chance developing their non-hospitalised counterparts. comorbidities at 3.35 2.97 risk compared without comorbidities. Similarly, already passed period 15 days 3 months recovery showed 3.06 1.85 odds above 6 Conclusion high living findings suggest need for appropriate interventions reduce complications

Language: Английский

---

Chinese herbal medicine for dyspnea and persistent symptoms of long COVID: a systematic review and meta-analysis of randomized controlled trials

Journal of Integrative Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Health-Related Quality of Life and Functional Status of Post-COVID-19 Patients

International Journal of Environmental Research and Public Health, Journal Year: 2025, Volume and Issue: 22(3), P. 338 - 338

Published: Feb. 25, 2025

COVID-19 mainly affects the respiratory system, although its manifestations are multisystemic. We increasingly recognizing complications that present after acute phase, which associated with impaired functional status and health-related quality of life (HRQoL). The objective was to assess HRQoL patients post-COVID-19. This a cross-sectional study involving individuals affected by who had persistent symptoms for one month phase disease. Functional measured six-minute walk test (6MWT), Fatigue Severity Scale (FSS), Medical Research Council (MRC) Dyspnea Scale, Post-COVID-19 Status (PCFS). confirmed Short-Form Health Survey 36 (SF-36). included 123 patients; 73 (59.35%) were male, mean age 49.17 ± 13.48 years body mass index 31.02 6.56 stratified into three groups: not-recovered group (NRG = 23), ward-recovered (WHG 60), intensive-care-unit (ICUG 40). main muscle weakness (74.17%) dyspnea (68.33%). predicted distances 6MWT missed 12.83% GNR group, 20.21% 28.82% UGCI group. MRC scale value less than 3, FSS over 4, indicating considerable fatigue. In PCFS scale, significant difference observed (p < 0.0005), while in SF-36, all domains compromised. involved this showed decline an impairment HRQoL.

Language: Английский

---

Hyper-reactivity of CD8+ T cells and high expression of IL-3 correlates with occurrence and severity of long-COVID

Clinical Immunology, Journal Year: 2025, Volume and Issue: 277, P. 110502 - 110502

Published: April 25, 2025

Following SARS-CoV-2 infection, some individuals develop Long-COVID-syndrome lasting for more than 3 months. We analyzed blood samples from patients with Long-COVID, controls without persistent symptoms following SARS-CoV-2-infection and non-infected donors a history of infection. Long-COVID showed clear signs T cell hyper-activation predominantly in the CD8+ subset 4-fold higher expression CD25 2-fold effector-memory cells. polyclonal stimulation, we found stronger upregulation 7-fold release IL-3 Long-COVID. Intracellular staining revealed 5-fold IL-3-expressing cells while GM-CSF, IFN-γ IL-2 were much less upregulated. These changes correlated severity persisted up to 18 months after Our data reveal pronounced long-lasting hyper-reactivity speak trial cell-immunosuppression

Language: Английский

---